**Juvéderm® Voluma® Approved in China for Temporal Hollows, Marking a New Milestone in Bone Structure Contouring**

ShanghaiMay 8, 2026 /PRNewswire/ — Allergan Aesthetics, a global medical aesthetics biopharmaceutical leader under AbbVie, announced that JUVÉDERM^® VOLUMA^® WITH LIDOCAINE has officially received approval from the China National Medical Products Administration (NMPA) for supraperiosteal injection in the temporal region to improve temporal hollowing. This makes it the first hyaluronic acid filler product approved in China for correcting temporal hollowing. The approval is supported by multi-center clinical data from the Chinese population, precisely implementing Allergan Aesthetics’ AA Signature™ concept of “Bone Beauty,” propelling China’s medical aesthetics into a new phase of high-quality development characterized by layered anti-aging, evidence-based treatment, and long-term standardized management.

Improving Temporal Hollowing: The “Upper Facial Anchor” of Bony Contour, Meeting the Structural Needs of Chinese Aesthetic Seekers

The temporal region is a key area connecting the upper and mid-face, directly influencing the smoothness of facial contours and visual harmony, serving as an important visual marker for facial rejuvenation^[1]. Affected by both the inherent skeletal characteristics of the Asian population and natural aging, temporal hollowing is a common structural concern among Chinese aesthetic seekers, which worsens with age.

Previously, there was a lack of approved compliant hyaluronic acid fillers for improving temporal hollowing in China. Clinical treatments often relied on empirical practices, lacking uniform standards in product selection, injection depth, and evaluation criteria. This approval establishes a clear reference pathway for clinical practice and provides more definitive treatment options for aesthetic seekers.

JUVÉDERM^® VOLUMA^® Approval: Based on Local Evidence, Offering a Stable and Predictable New Treatment Option for Clinical Practice

The anatomical structure of the temporal region is complex, imposing higher requirements on the filler material’s support, smooth transition capability, and safety. JUVÉDERM^® VOLUMA^® utilizes patented Vycross^® cross-linking technology, featuring a balanced ratio of elastic modulus and cohesivity^[2-4]. Through deep supraperiosteal injection, it provides structural support, better meeting the dual needs of the temporal region for structural support and natural contour. This approval is based on a Phase III multi-center, randomized, sham-controlled, evaluator-blinded study conducted in the Chinese population. Results showed an ATHS response rate of 90.5% at 6 months post-treatment, with both investigator and subject GAIS improvement scores exceeding 92%. Additionally, the product demonstrated good safety and tolerability.

Professor Li Qingfeng from Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, stated: “This study is one of the larger-scale, high-quality clinical studies targeting the Chinese population in the current field of temporal hollowing treatment. It provides important safety and longevity references for clinical practice, along with standardized assessment tools and reproducible diagnostic and treatment pathways. The approval of the temporal hollowing indication offers doctors and aesthetic seekers more definitive treatment options, making diagnosis and treatment more evidence-based and outcomes more predictable, while also providing significant practical support for the standardized development of the temporal filling field.”

AA Signature^TM Bone Beauty: Supporting China’s Medical Aesthetics Development Long-Term through Evidence-Based and Systematic Approaches

This approval further completes Allergan Aesthetics’ AA Signature™ Bone Beauty framework, synergizing with the approved medical aesthetics indication matrix of JUVÉDERM^® VOLUX^® (jawline), JUVÉDERM^® VOLUMA^® (nose/cheeks), and BOTOX^®. It establishes a comprehensive bony contour treatment matrix covering the “upper face – midface – lower face,” providing doctors with layered treatment references tailored to Asian characteristics, facilitating the transition from localized improvements to coordinated whole-face contour optimization, and offering aesthetic seekers a holistic facial aesthetic experience.

Professor Li Qin, President of the Facial Rejuvenation Branch of the Chinese Association of Plastics and Aesthetics, stated: “As aesthetic awareness evolves, aesthetic seekers increasingly pursue overall facial harmony and ‘natural bone beauty.’ The therapeutic value of the temporal region, as a key anchor point for upper facial contours, is gaining recognition. The approval of JUVÉDERM^® VOLUMA^® for temporal hollowing allows doctors to achieve synergistic effects of bony support and smooth contours through more scientific combined treatment strategies. This helps guide aesthetic seekers towards a long-term anti-aging concept of full-face design and phased treatment, safeguarding individual needs with systematic solutions—this is the utmost respect and protection for aesthetic seekers.”

For a long time, Allergan Aesthetics has been guided by evidence-based medicine. Through continuous professional medical education and standardized training, it helps doctors enhance their product application and aesthetic capabilities, progressing from practical exploration to standardized consensus. The implementation of the AA Signature™ Bone Beauty concept embodies this systematic approach—moving from single-point filling to overall contour optimization, driving the industry towards a more standardized and scientific direction.

Qiu Hanhua, Vice President and General Manager of Allergan Aesthetics China, stated: “The approval of JUVÉDERM^® VOLUMA^® for temporal hollowing is a significant step for Allergan Aesthetics in deepening its presence in the Chinese market and implementing the ‘Bone Beauty’ strategy. We remain committed to evidence-based medicine as our foundation, supporting the high-quality development of China’s medical aesthetics industry long-term through compliant products, standardized systems, and doctor empowerment, delivering contour aesthetic solutions that truly match the bony characteristics of the Asian population for aesthetic seekers.”